---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-083274"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2026-07-14T10:04:48+00:00"
generated_at: "2026-07-14T10:10:05.729880+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience raises ~$93.9M in registered direct offering of 3.78M shares at $26.48/share

## Summary
- Offering of 3,776,436 shares of common stock at $26.48 per share, expected to close July 14, 2026.
- Net proceeds estimated at $93.9M after underwriting discounts and expenses.
- Proceeds to accelerate clinical development of ALTO-207, including additional Phase 3 trial for treatment-resistant depression.
- Joint book-runners: BofA Securities, Stifel, William Blair, Robert W. Baird; co-managers: JonesTrading, H.C. Wainwright.

## SEC filing metadata
- accession: 0001104659-26-083274
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2026-07-14T10:04:48+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000110465926083274/0001104659-26-083274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000110465926083274/tm2620328d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-083274
- JSON: https://secwatch.observer/filing/0001104659-26-083274.json
- Plain text: https://secwatch.observer/filing/0001104659-26-083274.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.